,i #aagth ,,congress #ast ,session ,h4 ,r4 #cbeh ,,in ,,the ,,house ,,of ,,representatives ,may #ad1 #bjba ,ms4 ,sewell 7for herself and ,mr4 ,bilirakis7 introduced the following bill2 which was referred to the ,committee on ,energy and ,commerce ,a ,,bill ,to amend title ,,xxvii of the ,public ,health ,service ,act to improve patient access to anti-cancer oral medications1 and for other purposes4 #a4 ,short title ,this ,act may be cited as the ,timely ,access to ,cancer ,treatment ,act of #bjba or the ,,tact ,act of #bjba4 #b4 ,patient access to anti-,cancer oral medications 7a7 ,in general ,section #bgai;,a of the ,public ,health ,service ,act 7#db ,u4,s4,c4 #cjj;gg-#ai;,a7 is amended by adding at the end the following new subsection3 7f7 ,access to anti-,cancer oral medications 7#a7 ,requirements for contracts between group health plans or health insurance issuers and pharmacies ,if a group health plan or a health insurance issuer offering group or individual health insurance coverage covers or provides any benefits for anti-cancer oral medications 7as defined in paragraph 7#d77 and enters into a contract with a pharmacy1 whether directly or through an agent of such plan or issuer 7including a pharmacy benefit manager71 to dispense such medications to participants1 beneficiaries1 or enrollees of the plan or coverage1 such plan or issuer shall require1 as conditions of such contract1 such pharmacy to carry out the procedures described in paragraph 7#b74 7#b7 ,procedures described ,for purposes of paragraph 7#a71 the procedures described in this paragraph with respect to a participant1 beneficiary1 or enrollee of the plan or coverage and a health care provider who submits to such pharmacy a prescription for an anti-cancer oral medication for such participant1 beneficiary1 or enrollee are the following 7as applicable73 7,a7 ,pharmacy confirmation of ability to dispense ,not later than #bd hours after receiving such prescription-- 7i7 confirm to such health care provider that such pharmacy received such prescription2 and 7ii7 inform such health care provider1 as well as such plan or issuer1 whether such pharmacy will dispense such anti-cancer oral medication to such participant1 beneficiary1 or enrollee by not later than #gb hours after receiving such prescription1 including any time for benefits verification1 prior authorization1 or any other administrative procedure required by the agent of such plan or issuer 7including a pharmacy benefit manager7 prior to authorizing the pharmacy to dispense the medication4 7,b7 ,pharmacy able to fill prescription ,in the case that such pharmacy informs such health care provider in writing under subparagraph 7,a77ii7 that such pharmacy is able to dispense such anti-cancer oral medication to such participant1 beneficiary1 or enrollee by the #gb-;hour deadline described in such subparagraph1 dispense such anti-cancer oral medication to such participant1 beneficiary1 or enrollee by such deadline4 7,c7 ,pharmacy unable to fill prescription ,in the case that such pharmacy informs such health care provider under subparagraph 7,a77ii7 that such pharmacy is not able to dispense such anti-cancer oral medication to such participant1 beneficiary1 or enrollee by the #gb-;hour deadline described in such subparagraph1 immediately provide a written notice to-- 7i7 the prescribing physician or other health care provider2 7ii7 the group health plan or a health insurance issuer offering group or individual health insurance coverage2 and 7iii7 such participant1 beneficiary1 or enrollee2 with a clear and understandable explanation of such inability and of the option of such participant1 beneficiary1 or enrollee to be dispensed such anti-cancer oral medication from any provider or pharmacy described in paragraph 7#c77;,c71 in accordance with the cost-sharing requirements described in subparagraphs 7,a7 and 7,b7 of such paragraph4 7,d7 ,pharmacy ,failure to ,communicate ,if the pharmacy does not communicate its ability to dispense as required by subparagraph 7,a71 or1 after confirming that it will dispense an anti-cancer oral medication under such subparagraph1 does not actually dispense such medication by the #gb-;hour deadline described in such paragraph1 such pharmacy shall be deemed to have confirmed that it is not able to dispense such medication under subparagraph 7,c74 7#c7 ,requirements for group health plans and health insurance issuers 7,a7 ,patient selection of alternate provider or pharmacy ,if a group health plan or a health insurance issuer offering group or individual health insurance coverage 7or its agent1 including a pharmacy benefits manager7 described in paragraph 7#a7 enters into a contract described in such paragraph1 with a pharmacy and such pharmacy1 with respect to a participant1 beneficiary1 or enrollee of the plan or coverage and health care provider who submits to such pharmacy a prescription for an anti-cancer oral medication for such participant1 beneficiary1 or enrollee1 informs such health care provider under subparagraph 7,a77ii7 of such paragraph that such pharmacy will not dispense such anti-cancer oral medication to such participant1 beneficiary1 or enrollee by the #gb-;hour deadline described in such subparagraph 7or in the case that the participant1 beneficiary1 or enrollee has not received the anti-cancer oral medication by the #gb-;hour deadline71 the plan or issuer-- 7i7 shall authorize such participant1 beneficiary1 or enrollee to select any provider or pharmacy described in subparagraph 7,c7 to dispense such anti-cancer oral medication to such participant1 beneficiary1 or enrollee based on the written noticed described in paragraph 7#b77;,c7 or a certification by the prescribing physician or other health professional that the participant1 beneficiary1 or enrollee has not received the anti-cancer oral medication by the #gb-;hour deadline2 and 7ii7 in the case the provider or pharmacy selected under clause 7i7 does not have a contract with such plan or issuer to dispense such anti-cancer oral medication to such participant1 group health plan or health insurance issuer offering group or individual health insurance coverage described in paragraph 7#a7 shall cover the medication and pay the provider or pharmacy in accordance with the provisions of subparagraph 7,b74 7,b7 ,coverage requirements for prescriptions dispensed by alternate provider or pharmacy ,for prescriptions dispensed by an alternate provider or pharmacy in accordance with subparagraph 7,a7 that does not have a contract with a group health plan or a health insurance issuer offering group or individual health insurance coverage 7or its agent1 including a pharmacy benefits manager7 described in paragraph 7#a7 to dispense such anti-cancer oral medication to such participant1 such group health plan or a health insurance issuer 7or its agent1 including a pharmacy benefits manager7 shall cover the medication and pay the provider or pharmacy subject the following requirements-- 7i7 such medication will be provider without imposing any requirement under the plan for prior authorization of the medication or any limitation on coverage that is more restrictive than the requirements or limitations that apply to anti-cancer oral medications received from participating providers and pharmacies with respect to such plan2 7ii7 the cost-sharing requirement 7expressed as a copayment amount or coinsurance rate7 is not greater than the requirement that would apply if such services were provided by a participating provider or a participating pharmacy2 7iii7 such cost-sharing requirement is calculated as if the total amount that would have been charged for such services by such participating provider or participating pharmacy were equal to the recognized amount 7as determined by the ,secretary7 for such anti-cancer oral medications1 plan1 and year2 7iv7 the group health plan pays to such provider or pharmacy1 respectively1 the amount by which the recognized amount for such services and year involved exceeds the cost-sharing amount for such services 7as determined in accordance with clauses 7ii7 and 7iii77 and year2 7v7 any cost-sharing payments made by the participant or beneficiary with respect to such anti-cancer oral medication so furnished shall be counted toward any in-network deductible or out-of-pocket maximums applied under the plan 7and such in-network deductible and out-of-pocket maximums shall be applied7 in the same manner as if such cost-sharing payments were made with respect to anti-cancer oral medication furnished by a participating provider or a participating pharmacy2 and 7vi7 such medication will be provided without regard to any other term or condition of such coverage 7other than exclusion or coordination of benefits1 or an affiliation or waiting period1 permitted under section #bgjd of this ,act1 including as incorporated pursuant to section #gae of the ,employee ,retirement ,income ,security ,act of #aigd and section #ihae of this ,act1 and other than applicable cost-sharing74 7,c7 ,provider or pharmacy described ,a provider or pharmacy described in this subparagraph1 with respect to a participant1 beneficiary1 or enrollee of a group health plan or group or individual health insurance coverage described in paragraph 7#a7 and a prescription for an anticancer oral medication for such participant1 beneficiary or enrollee1 is a provider or pharmacy that-- 7i7 is licensed by the ,state in which such provider or pharmacy is located to dispense such anti-cancer oral medication1 if such a license is required by the ,state2 7ii7 is either located within a reasonable distance 7as determined by the ,secretary7 of the residence of such participant1 beneficiary1 or enrollee1 or is able to deliver such anti-cancer oral medication to such participant1 beneficiary1 or enrollee at such residence2 and 7iii7 is able to dispense 7and if applicable1 deliver71 such anti-cancer oral medication to such participant1 beneficiary1 or enrollee within #dh hours of the date on which it receives the prescription4 ,for purposes of this section1 a provider or pharmacy described in this subparagraph includes a physician or other health care practitioner authorized to dispense anti-cancer oral medication to such participant1 beneficiary1 or enrollee pursuant to the law of the ,state in which the physician or other health care practitioner is located4 7,d7 ,prior authorization requirements ,in the case of a group health plan or a health insurance issuer offering group or individual health insurance coverage that requires prior authorization for an anti-cancer oral medication to be dispensed to a participant1 beneficiary1 or enrollee of the plan or coverage1 such plan or issuer 7or its agent 1 including a pharmacy benefits manager7 shall make a decision with respect to a request for such a prior authorization by not later than #gb hours after receiving such request4 ,in the case that such plan or issuer 7or its agent1 including a pharmacy benefits manager7 does not make a decision with respect to a request for prior authorization for an anticancer oral medication to be dispensed to a participant1 beneficiary1 or enrollee of the plan or coverage by the #gb-;hour deadline described in the previous sentence1 such participant1 beneficiary or enrollee may select any pharmacy described in subparagraph 7,c7 to dispense such anticancer oral medication to such participant1 beneficiary1 or enrollee1 in accordance with the cost-sharing requirements described in subparagraph 7,b7 but only if the prescription for such anti-cancer oral medication meets the clinical guidelines set forth by the ,national ,comprehensive ,cancer ,network4 7#d7 ,anti-cancer oral medication defined ,in this subsection1 the term anti-cancer oral medication means a drug or biological 7as defined in section #ahfa7t7 of the ,social ,security ,act7 that is used in an anti-cancer chemotherapeutic regimen for a medically accepted indication1 including any related supportive care drugs and biologicals that are dispensed as an outpatient and taken by the mouth4 4 7b7 ,effective date ,the amendments made by this section shall apply with respect to plan years beginning on or after ,january #a1 #bjbb4 7c7 ,,gao report and recommendations 7#a7 ,in general ,not later than #b years after the date of enactment of this ,act1 the ,comptroller ,general of the ,united ,states shall submit to the ,chair and ,ranking ,member of the ,committee on ,health1 ,education1 ,labor and ,pensions of the ,senate and the ,chair and ,ranking ,member of the ,committee on ,energy and ,commerce of the ,house of ,representatives a report on the effects of the implementation of subsection 7f7 of section #bgai;,a of the ,public ,health ,service ,act 7as added by subsection 7a77 on the timely access of patients to anti-cancer oral medications 7as defined in subsection 7f77#d7 of such section71 together with such recommendations as the ,comptroller ,general determines are appropriate4 7#b7 ,items included ,the report submitted under paragraph 7#a7 shall include-- 7,a7 a comparison of the amount of time between the date on which a prescription is written and the date on which a patient receives an anti-cancer oral medication before and after the implementation of subsection 7f7 of section #bgai;,a of the ,public ,health ,service ,act2 7,b7 an assessment of the effects on patient health outcomes1 including morbidity and mortality2 7,c7 an evaluation of costs to patients1 health insurance issuers1 physicians1 and other healthcare providers2 and 7,d7 a risk assessment with mitigation recommendations on any actual or potential fraud1 waste and abuse relating to the implementation of such subsection4